Patents by Inventor Thierry Berney

Thierry Berney has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-TLR4 ANTIBODIES AND USES THEREOF
    Publication number: 20200239566
    Abstract: This invention relates generally to antibodies that specifically bind Toll-like Receptor 4 (TLR-4), and to methods of using the anti-TLR4 antibodies as therapeutics and to methods of using the anti-TLR4 antibodies in methods of preventing transplant rejection and/or prolonging survival of transplanted biological material.
    Type: Application
    Filed: August 15, 2019
    Publication date: July 30, 2020
    Inventors: Marie KOSCO-VILBOIS, Katrien DEGRAAF, Thierry BERNEY, Laurianne Santa GIOVANNONI, Domenic BOSCO
  • Anti-TLR4 antibodies and uses thereof
    Patent number: 10421809
    Abstract: This invention relates generally to antibodies that specifically bind Toll-like Receptor 4 (TLR-4), and to methods of using the anti-TLR4 antibodies as therapeutics and to methods of using the anti-TLR4 antibodies in methods of preventing transplant rejection and/or prolonging survival of transplanted biological material.
    Type: Grant
    Filed: December 6, 2016
    Date of Patent: September 24, 2019
    Assignee: NovImmune SA
    Inventors: Marie Kosco-Vilbois, Katrien De Graaf, Thierry Berney, Laurianne Santa Giovannoni, Domenic Bosco
  • ANTI-TLR4 ANTIBODIES AND USES THEREOF
    Publication number: 20170267754
    Abstract: This invention relates generally to antibodies that specifically bind Toll-like Receptor 4 (TLR-4), and to methods of using the anti-TLR4 antibodies as therapeutics and to methods of using the anti-TLR4 antibodies in methods of preventing transplant rejection and/or prolonging survival of transplanted biological material.
    Type: Application
    Filed: December 6, 2016
    Publication date: September 21, 2017
    Inventors: Marie Kosco-Vilbois, Katrien De Graaf, Thierry Berney, Laurianne Santa Giovannoni, Domenic Bosco
  • Anti-TLR4 antibodies and methods of use thereof
    Patent number: 9512221
    Abstract: This invention relates generally to antibodies that specifically bind Toll-like Receptor 4 (TLR-4), and to methods of using the anti-TLR4 antibodies as therapeutics and to methods of using the anti-TLR4 antibodies in methods of preventing transplant rejection and/or prolonging survival of transplanted biological material.
    Type: Grant
    Filed: May 15, 2014
    Date of Patent: December 6, 2016
    Assignee: NOVIMMUNE S.A.
    Inventors: Marie Kosco-Vilbois, Katrien L. De Graaf, Thierry Berney, Santa Giovannoni, Domenic Bosco
  • ANTI-TLR4 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20150010559
    Abstract: This invention relates generally to antibodies that specifically bind Toll-like Receptor 4 (TLR-4), and to methods of using the anti-TLR4 antibodies as therapeutics and to methods of using the anti-TLR4 antibodies in methods of preventing transplant rejection and/or prolonging survival of transplanted biological material.
    Type: Application
    Filed: May 15, 2014
    Publication date: January 8, 2015
    Applicant: NovImmune S.A.
    Inventors: Marie Kosco-Vilbois, Katrien L. De Graaf, Thierry Berney, Santa Giovannoni, Domenic Bosco
  • Neutral protease (NP) and product by using neutral protease for tissue dissociation as well as method for the production thereof
    Patent number: 8765471
    Abstract: The use of a neutral protease (NP) together with a collagenase consists in that a neutral protease which is not contained in a collagenase enzyme preparation and which is not produced by a recombinant production is mixed before the beginning of a tissue dissociation with a collagenase or a collagenase enzyme preparation with an individual dosage of the quantitative proportions of neutral protease and collagenase for improving the isolation results with respect to yield, viability and integrity of the cells.
    Type: Grant
    Filed: April 15, 2013
    Date of Patent: July 1, 2014
    Assignee: Nordmark Arzneimittel GmbH & Co. KG
    Inventors: Manfred Kurfuerst, Christian Raemsch, Nicole Raemsch-Guenther, Olaf Friedrich, Silke Huettler, Daniel Brandhorst, Thierry Berney, Pascal Bucher, Heide Brandhorst
  • Anti-TLR4 antibodies and methods of use thereof
    Patent number: 8734790
    Abstract: This invention relates generally to antibodies that specifically bind Toll-like Receptor 4 (TLR-4), and to methods of using the anti-TLR4 antibodies as therapeutics and to methods of using the anti-TLR4 antibodies in methods of preventing transplant rejection and/or prolonging survival of transplanted biological material.
    Type: Grant
    Filed: January 10, 2012
    Date of Patent: May 27, 2014
    Assignee: Novimmune SA
    Inventors: Marie Kosco-Vilbois, Katrien L. De Graaf, Thierry Berney, Laurianne Santa Giovannoni, Domenic Bosco
  • NEUTRAL PROTEASE (NP) AND PRODUCT BY USING NEUTRAL PROTEASE FOR TISSUE DISSOCIATION AS WELL AS METHOD FOR THE PRODUCTION THEREOF
    Publication number: 20130230922
    Abstract: The use of a neutral protease (NP) together with a collagenase consists in that a neutral protease which is not contained in a collagenase enzyme preparation and which is not produced by a recombinant production is mixed before the beginning of a tissue dissociation with a collagenase or a collagenase enzyme preparation with an individual dosage of the quantitative proportions of neutral protease and collagenase for improving the isolation results with respect to yield, viability and integrity of the cells.
    Type: Application
    Filed: April 15, 2013
    Publication date: September 5, 2013
    Applicant: Nordmark, Arzneimittel GmbH & Co., KG
    Inventors: Manfred KURFUERST, Christian Raemsch, Nicole Raemsch-Guenther, Olaf Friedrich, Silke Huettler, Daniel Brandhorst, Thierry Berney, Pascal Bucher, Heide Brandhorst
  • Neutral protease (NP) and product by using neutral protease for tissue dissociation as well as method for the production thereof
    Patent number: 8440445
    Abstract: The use of a neutral protease (NP) together with a collagenase consists in that a neutral protease which is not contained in a collagenase enzyme preparation and which is not produced by a recombinant production ia mixed before the beginning of a tissue dissociation with a collagenase or a collagenase enzyme preparation with an individual dosage of the quantitative proportions of neutral protease and collagenase for improving the isolation results with respect to yield, viability and integrity of the cells.
    Type: Grant
    Filed: June 16, 2004
    Date of Patent: May 14, 2013
    Assignee: Nordmark Arzneimittel GmbH & Co. KG
    Inventors: Manfred Kurfürst, Christian Raemsch, Nicole Raemsch-Guenther, Olaf Friedrich, Silke Huettler, Daniel Brandhorst, Thierry Berney, Pascal Bucher, Heide Brandhorst
  • ANTI-TLR4 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20120177648
    Abstract: This invention relates generally to antibodies that specifically bind Toll-like Receptor 4 (TLR-4), and to methods of using the anti-TLR4 antibodies as therapeutics and to methods of using the anti-TLR4 antibodies in methods of preventing transplant rejection and/or prolonging survival of transplanted biological material.
    Type: Application
    Filed: January 10, 2012
    Publication date: July 12, 2012
    Inventors: Marie Kosco-Vilbois, Katrien L. De Graaf, Thierry Berney, Laurianne S. Giovannoni, Domenic Bosco
  • Neutral protease (NP) and product by using neutral protease for tissue dissociation as well as method for the production thereof
    Publication number: 20050142632
    Abstract: The use of a neutral protease (NP) together with a collagenase consists in that a neutral protease which is not contained in a collagenase enzyme preparation and which is not produced by a recombinant production ia mixed before the beginning of a tissue dissociation with a collagenase or a collagenase enzyme preparation with an individual dosage of the quantitative proportions of neutral protease and collagenase for improving the isolation results with respect to yield, viability and integrity of the cells.
    Type: Application
    Filed: June 16, 2004
    Publication date: June 30, 2005
    Inventors: Manfred Kurfurst, Christian Raemsch, Nicole Raemsch-Guenther, Olaf Friedrich, Silke Huettler, Daniel Brandhorst, Thierry Berney, Pascal Bucher, Heide Brandhorst